Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Reba Goshert

Nurse Practitioner, Pediatrics Nappanee, IN Nurse Practitioner

NPI 1912103151 CMS profile 11213457

2102 N Main St, Nappanee, IN 46550

Open in the dashboard

General payments

$3,495

213 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Reba Goshert of Nappanee, IN is reported in the CMS Open Payments database as having received $3,495 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $358 21
2024 General $533 32
2023 General $789 45
2022 General $837 53
2021 General $978 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Reba Goshert
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Reba Goshert were reported at $358. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Reba Goshert Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $978 $60 $23–$142 $132
2022 $837 $72 $27–$161 $149
2023 $789 $89 $35–$185 $160
2024 $533 $93 $34–$199 $164
2025 $358 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $444 27 payments
  2. AbbVie, Inc. $432 23 payments
  3. Pfizer Inc. $395 27 payments
  4. Lilly USA, LLC $233 16 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $228 16 payments
  6. Novo Nordisk Inc $227 14 payments
  7. GlaxoSmithKline, LLC. $142 9 payments
  8. Welch Allyn $125 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $110 6 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $101 6 payments
  11. Other $1,058 68 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,370 212 payments
  2. Debt forgiveness $125 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $250 12 payments
  2. PREVNAR 20 $215 15 payments
  3. BREZTRI $197 12 payments
  4. Ozempic $195 12 payments
  5. COMIRNATY $185 13 payments
  6. JARDIANCE Diabetes $182 13 payments
  7. RYBELSUS $177 11 payments
  8. JARDIANCE Diabetes $174 12 payments
  9. AIRSUPRA $159 9 payments
  10. ABRYSVO $126 9 payments
  11. Other $2,976 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

3,113

Median for Nurse Practitioner: 389

Drug cost

$207,550

Median for Nurse Practitioner: $21,885

Branded share of claims

15.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 31 $52,242
Mounjaro Tirzepatide Brand 21 $40,612
Trulicity Dulaglutide Brand 27 $28,511
Xarelto Rivaroxaban Brand 12 $19,029
Januvia Sitagliptin Phosphate Brand 13 $18,551
Eliquis Apixaban Brand 17 $17,973
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 30 $5,837
Levothyroxine Sodium Generic 248 $1,707
Omeprazole Generic 125 $1,507
Diclofenac Sodium Generic 16 $1,169

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$24,164

Of which drugs: $4,612

Medicare patients

157

Average age 75

Services billed

529

122 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 36%
Diabetes 28%
Ischemic heart disease 22%
Osteoporosis 22%
Depression 19%
Chronic kidney disease 16%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 20 20 $1,617

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $84
$84 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $74
$74 — —
JARDIANCE
  • Lilly USA, LLC $38
  • Boehringer Ingelheim Pharmaceuticals, Inc. $14
$52 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $42
$42 — —
ABRYSVO
  • PFIZER INC. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Pediatrics in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record